BackgroundThere is growing interest in glutamatergic agents in depression, particularly
ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist. We aimed to …

Objective: The N-methyl-d-aspartate receptor antagonist ketamine has rapid antidepressant
effects in treatment-resistant major depressive disorder (MDD) and bipolar depression …

The most recent data from the Global Burden of Disease Study highlight that 47.5%(ie, 183.9
million) of all disability-adjusted life years are attributable to mood disorders with an …

Objective: Ketamine has emerged as a rapid-acting antidepressant, though controversy
remains whether sufficient data exist to justify its use outside of research protocols. In …

Ketamine, administered in subanesthetic doses, is gaining recognition as an off-label
treatment for severe and even treatment-refractory depression. This article explores potential …

Ketamine is an anesthetic drug that is also used for off-label indications such as the
mediation of analgesia and sedation in various settings. It is additionally recognized as an …

Objective Single-dose intravenous (IV) injection of ketamine has shown rapid but transient
antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain …

The rapid antidepressant effect of ketamine has become a breakthrough in the research and
treatment of depression. Although predictive and modulating factors of the response to …

There is an urgent need for more rapidly effective pharmacotherapies for major depressive
disorder and bipolar disorder (BP) that are efficacious and tolerable for depressed patients …

Objective This pilot study assessed the feasibility, efficacy and safety of an individual dose‐
titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) …